The objective of this study is to investigate, as a proof-of-principle, long-term (52 weeks) effects of tirzepatide once-weekly vs. placebo on changes in coronary plaque composition and progression (assessed by NIRS), plaque burden (assessed by IVUS) and microvascular function (assessed by invasively measured CFR) in overweight and obese individuals with stable coronary artery disease (CAD). In addition, the objective of a baseline cross-sectional sub-study is to explore potential metabolic and cardiovascular (CV) predictors for high arteriosclerotic plaque burden in overweight and obese individuals and to establish a cohort for future research projects.
Informed written consent
BMI equal to or above 27 kg/m2
Age 18 years or older
Referred to coronary angiogram (CAG) due to stable angina
History of diabetes or HbA1c ≥48 mmol/mol (6.5%) at baseline
Treatment with Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA)
History of coronary artery bypass surgery (CABG)
Planned CV intervention (including percutaneous coronary intervention, cardiac surgery or transcatheter valve intervention) at time of randomisation
Tina Vilsbøll
Lead sponsor
Steno Diabetes Center Copenhagen
Sponsor institution